natgillin/translations-raw huggingface dataset:
Other hypersensitivity reactions
Druge reakcije preosjetljivosti
• Weeks 2-4 (day 8-28):
• od 2. do 4. tjedna (od 8. do 28. dana):
Your doctor will decide if you should take this medicine while breast-feeding.
Liječnik će odlučiti trebate li uzimati ovaj lijek dok dojite.
Talk to your doctor before and after taking NUEDEXTA if:
Obratite se liječniku prije i nakon uzimanja lijeka NUEDEXTA:
Treatment of hypotension and of other signs and symptoms should be directed at symptomatic and supportive measures.
Liječenje hipotenzije i drugih znakova i simptoma treba biti usmjereno na simptomatske i potporne mjere.
Take your next dose at the usual time and make sure that approximately 12 hours passes between two doses.
Svoju sljedeću dozu uzmite u uobičajeno vrijeme i vodite računa da je između dviju doza prošlo približno 12 sati.
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, or if you are not using reliable contraception, ask your doctor for advice before taking this medicine.
Ako ste trudni ili dojite, mislite da biste mogli biti trudni ili planirate trudnoću ili ne rabite pouzdanu kontracepciju, obratite se liječniku za savjet prije nego što uzmete ovaj lijek.
Pharmacotherapeutic group: Other nervous system drugs; ATC code: N07XX59
Farmakoterapijska skupina: Drugi lijekovi s djelovanjem na živčani sustav; ATK oznaka: N07XX59
Day 9
9. dan
What NUEDEXTA is and what it is used for
Što je NUEDEXTA i za što se koristi
If you have certain heart problems or are currently taking certain other medicines, NUEDEXTA may not be appropriate for you, or your doctor may want to monitor your heart activity when you start NUEDEXTA.
Ako imate određenih srčanih tegoba ili sada uzimate neke druge lijekove, NUEDEXTA možda za Vas nije prikladan lijek, a možda će Vam liječnik htjeti nadzirati rad srca kada počnete uzimati lijek NUEDEXTA.
Paroxetine exposure (AUC0-24) increased by 1.7 fold and Cmax increased by 1.5 fold.
Izloženost paroksetinu (AUC0-24) povećala se 1,7 puta, a Cmax 1,5 puta.
• Studies to Assess Cardiac Effects
• Ispitivanja za procjenu učinaka na srčanu aktivnost
Each bottle will be contained within a carton.
Svaka bočica nalazi se u kutiji.
In addition it shows affinity for the serotonin transporter (SERT) and for the 5-HT1B/D receptor.
Osim toga, pokazuje afinitet za serotoninski prijenosnik (SERT) te za receptor 5-HT1B/D.
Hepatitis, including granulomatous hepatitis, has been reported in patients receiving quinidine, generally during the first few weeks of therapy.
Hepatitis, uključujući granulomatozni hepatitis, prijavljen je u bolesnika koji su primali kinidin, obično u prvih nekoliko tjedana terapije.
The most important effects of acute overdoses are ventricular arrhythmias and hypotension.
Najvažniji učinci akutnog predoziranja jesu ventrikularne aritmije i hipotenzija.
In addition, the maintenance of the clinical effect of NUEDEXTA in the patient should be regularly monitored in the long-term against its tolerability, in order to ascertain the continued benefit of the product.
Osim toga, održavanje kliničkog učinka lijeka NUEDEXTA u bolesnika treba redovito nadzirati na dugi rok u odnosu na podnošljivost, kako bi se potvrdila stalna korist lijeka.
• atomoxetine, used to treat attention-deficit hyperactivity disorder (ADHD)
• atomoksetin za liječenje poremećaja pomanjkanja pažnje s hiperaktivnošću (ADHD)
• Week 1 (day 1-7):
• 1. tjedan (od 1. do 7. dana):
If you take more NUEDEXTA than you should
Ako uzmete više lijeka NUEDEXTA nego što ste trebali
Other medicines and NUEDEXTA
Drugi lijekovi i NUEDEXTA
• tamoxifen, used to treat or prevent some cancers
• tamoksifen, koristi se za liječenje i sprječavanje nekih vrsta raka
ritonavir, saquinavir, amprenavir, fosamprenavir
ritonavir, sakvinavir, amprenavir, fosamprenavir
There are several hydroxylated metabolites of quinidine.
Postoji nekoliko hidroksiliranih metabolita kinidina.
Quinidine
Kinidin
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from NUEDEXTA therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Potrebno je odlučiti prekinuti li dojenje ili prekinuti liječenje/suzdržati se od liječenja NUEDEXTOM uzimajući u obzir korist dojenja za dijete i korist liječenja za ženu.
If any of the above occur, stop taking the capsules and tell your doctor immediately
Ako se nešto od gore navedenog pojavi Vama, prekinite s uzimanjem kapsula i odmah obavijestite liječnika.
Quinidine clearance is unaffected, although there is an increased volume of distribution that leads to an increase in the elimination half-life.
Klirens kinidina nije zahvaćen, iako postoji povećan volumen distribucije koji dovodi do povećanog poluvremena eliminacije.
Anticholinergic effects of quinidine
Antikolinergički učinci kinidina
Your doctor will closely monitor you for side effects and/or may need to adjust the dose of the other medicine or NUEDEXTA.
Liječnik će kod Vas pažljivo nadzirati moguću pojavu nuspojava i/ili će možda trebati prilagoditi dozu drugog lijeka ili lijeka NUEDEXTA.
• medicines to reduce pain and/or cough, such as codeine and hydrocodone
• lijekovi za ublažavanje bolova i/ili kašlja kao što su kodein i hidrokodon
• increased liver enzymes (GGT, AST, ALT)
• povišeni jetreni enzimi (GGT, AST, ALT)
• double vision, blurred vision
• dvostruke slike, zamućen vid
• excessive muscle stiffness (spasticity)
• prekomjerno ukočenost mišića (spastičnost)
Studies in animals (rats and rabbits) have shown developmental toxicity, including teratogenicity and embryolethality (see section 5.3).
Ispitivanja na životinjama (štakori i kunići) pokazala su razvojnu toksičnost, uključujući teratogenost i smrtnost embrija (vidjeti dio 5.3).
ECG should be re-evaluated if risk factors for QTc prolongation change significantly during treatment with NUEDEXTA.
EKG procjenu treba ponoviti, ako se čimbenici rizika za produljenje QTc intervala značajno promijene tijekom terapije NUEDEXTOM.
• if you are allergic to dextromethorphan, quinidine or any of the other ingredients of this medicine (listed in section 6).
• ako ste alergični na dekstrometorfan, kinidin ili neki drugi sastojak ovog lijeka (naveden u dijelu 6).
NUEDEXTA should be discontinued if hepatitis occurs unless it is clearly not treatment related.
NUEDEXTA se treba obustaviti ako se pojavi hepatitis, osim kad je jasno da nije povezan s liječenjem.
The clinical relevance of this observation to drugs that are OCT1 substrates, such as metformin, is unknown.
Nije poznata klinička važnost ovog opažanja za lijekove koji su supstrati OCT1, primjerice metformin.
• travel or motion sickness, ringing in the ears (tinnitus)
• bolest kretanja ili putovanja, zvonjava u ušima (tinitus)
What NUEDEXTA is and what it is used for What you need to know before you take NUEDEXTA How to take NUEDEXTA
Što je NUEDEXTA i za što se koristi Što morate znati prije nego počnete uzimati lijek NUEDEXTA
• you have problems with your liver or kidney.
• imate tegoba s jetrom ili bubrezima.
When NUEDEXTA is used with other serotoninergic medicines, the risk of “serotonin syndrome” may be increased due to pharmacodynamic interaction.
Kada se NUEDEXTA uzima s drugim serotoninergičkim lijekovima, rizik od „serotoninskog sindroma“ može se povećati zbog farmakodinamičkih interakcija.
• The active substances are:
• Djelatne tvari su:
How to store NUEDEXTA Contents of the pack and other information
Kako čuvati lijek NUEDEXTA Sadržaj pakiranja i druge informacije
Caution is required when administering NUEDEXTA in combination with flecainide, chlorpromazine and haloperidol.
Oprez je potreban kada se NUEDEXTA primjenjuje u kombinaciji s flekainidom, klorpromazinom i haloperidolom.
Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.
Bolesnici s rijetkim nasljednim poremećajima nepodnošenja galaktoze, nedostatka Lapp laktaze ili malapsorpcije glukoze-galaktoze ne smiju uzimati ovaj lijek.
When the urine pH is less than 7, about 20% of administered quinidine appears unchanged in the urine, but this fraction drops to as little as 5% when the urine is more alkaline.
Kada je pH mokraće manji od 7, oko 20% primijenjenog kinidina pojavi se nepromijenjeno u mokraći, ali ta frakcija padne na samo 5% ako je mokraća lužnatija.
telithromycin, erythromycin and rifampicin
telitromicin, eritromicin i rifampicin
In the pre and post-natal developmental study, slight developmental delay was seen in offspring at the mid- and high-doses.
U ispitivanju prenatalnog i postnatalnog razvoja, ustanovljeno je neznatno razvojno zaostajanje potomstva pri srednjim i visokim dozama.
Interaction with NUEDEXTA may result in an increased effect on QT interval (see sections 4.4 and 4.5).
Posljedica interakcije s NUEDEXTOM može biti povećani učinak na QT interval (vidjeti dijelove 4.4 i 4.5).
However, cases of dextromethorphan abuse have been reported, predominately in adolescents.
Međutim, slučajevi zlouporabe dekstrometorfana prijavljeni su uglavnom u adolescenata.
This may lead to lower, potentially subtherapeutic plasma concentrations of dextromethorphan and decreased efficacy of NUEDEXTA.
To može dovesti do nižih, potencijalno subterapijskih plazmatskih koncentracija dekstrometorfana i smanjene djelotvornosti lijeka NUEDEXTA.
• medicines used to treat bacterial infections, including tuberculosis, containing clarithromycin,
• lijekovi protiv bakterijskih infekcija, uključujući tuberkulozu, koji sadrže klaritromicin,
• if you have a heart problem called “complete heart block” or “long QT syndrome” or have had a problem with your heart called “torsades de pointes”.
• ako imate srčanu tegobu pod nazivom „potpuni srčani blok“ ili „sindrom dugog QT intervala“ ili ste imali tegobu sa srcem pod nazivom „torsades de pointes“.
NUEDEXTA may be taken without regard to meals as food does not affect the exposure of dextromethorphan and quinidine significantly.
NUEDEXTA se može uzimati bez obzira na obroke, jer hrana ne utječe značajno na izloženost dekstrometorfanu i kinidinu.
If you have been told by your doctor that you have intolerance to some sugars, contact your doctor before taking this medicine.
Ako Vam je liječnik rekao da ne podnosite neke šećere, obratite se svom liječniku prije nego uzmete ovaj lijek.
Depending on the severity of your problems, your doctor may carefully consider whether this medicine is suitable for you and monitor you more closely for potential side effects.
Ovisno o težini Vaših tegoba, liječnik može pažljivo razmotriti je li ovaj lijek za Vas prikladan i pomnije Vas motriti zbog mogućih nuspojava.
Drugs that delay elimination of quinidine (cimetidine, carbonic anhydrase inhibitors, thiazide diuretics) should be withdrawn unless absolutely required.
Lijekove koji odgađaju eliminaciju kinidina (cimetidin, inhibitori ugljične anhidraze, tijazidni diuretici) treba ukinuti, osim kad su neosporno potrebni.
A list of all other side effects is provided below:
Popis drugih nuspojava nalazi se ispod:
• From the eighth day of treatment onwards: two capsules per day, one in the morning and one in the evening, 12 hours apart.
• od osmog dana liječenja nadalje: dvije kapsule na dan, jedna ujutro i jedna uvečer, s razmakom od 12 sati.
Patients should be monitored for worsening clinical condition in myasthenia gravis and other conditions that may be adversely affected by anticholinergic effects.
Bolesnike treba nadzirati zbog mogućeg pogoršanja kliničkog stanja u miasteniji gravis i drugim stanjima na koja mogu loše utjecati antikolinergički učinci.
Dextromethorphan may increase the risk of serotonin syndrome, and this risk is increased by overdose, particularly if taken with other serotonergic agents, SSRIs or tricyclic antidepressants.
Dekstrometorfan može povećati rizik od serotoninskog sindroma, a taj se rizik povećava predoziranjem, posebice ako je lijek uzet s drugim serotonergičnim agensima, SSRI ili tricikličkim antidepresivima.
A population pharmacokinetic analysis revealed similar pharmacokinetics in patients <65 years and those ≥65 years of age (see section 5.2).
Analiza populacijske farmakokinetike pokazala je sličnu farmakokinetiku u bolesnika u dobi <65 godina i onih ≥65 godina (vidjeti dio 5.2).
Due to the possibility of dextromethorphan abuse, physicians should evaluate patients for a history of drug abuse, and observe such patients closely for signs of misuse or abuse (e.g. development of tolerance, increases in dose, drug-seeking behaviour).
Zbog moguće zlouporabe dekstrometorfana, liječnici trebaju procijeniti bolesnika s obzirom na zlouporabu droga u anamnezi te pažljivo pratiti takve bolesnike zbog znakova pogrešne upotrebe ili zlouporabe (npr. razvoj tolerancije, povećanje doze, ovisničko ponašanje).
If NUEDEXTA and paroxetine are prescribed concomitantly, the initial dose of paroxetine should be reduced.
Ako je propisana istovremena primjena lijeka NUEDEXTA i paroksetina, potrebno je smanjiti početnu dozu paroksetina.
• heart problems, such as slow, fast or irregular heart beat, or altered results during an electrocardiogram (ECG - QT prolongation)
• srčane tegobe kao što su spori, brzi ili nepravilni srčani otkucaji ili promijenjeni rezultati dobiveni snimanjem elektrokardiograma (EKG - produljenje QT intervala)
Caution should be used when this medicinal product is taken in combination with alcohol or other centrally acting medicinal products that might increase the risk of adverse reactions such as somnolence and dizziness.
Potreban je oprez kada se ovaj lijek uzima u kombinciji s alkoholom ili drugim lijekovima s centralnim djelovanjem, koji bi mogli povećati rizik od nuspojava, kao što su somnolencija i omaglica.
What NUEDEXTA contains
Što NUEDEXTA sadrži
Evaluation and treatment of overdose is based on experience with the individual components, dextromethorphan and quinidine.
Procjena i liječenje predoziranja temelji se na iskustvu s pojedinačnim komponentama, dekstrometorfanom i kinidinom.
When taking two capsules within 24 hours, the recommended dose interval is 12 hours.
Kada se uzimaju dvije kapsule unutar 24 sata, preporučeni dozni interval iznosi 12 sati.
• if you take a medicine called thioridazine, which is used for mental illness but can also affect the heart.
• ako uzimate lijek pod nazivom tioridazin, koji se koristi pri duševnoj bolesti, ali može također utjecati na srce.
Please tell your doctor if you are taking any of the following medicines, as your doctor will closely monitor you for side effects.
Molimo obavijestite liječnika ako uzimate neki od ovih lijekova jer će Vas liječnik pažljivo pratiti zbog nuspojava.
• you have had at any time a serious condition called “serotonin syndrome”, which can be caused by certain medicines e.g. antidepressants.
• ako ste ikada prije imali ozbiljnu bolest koja se naziva „serotoninski sindrom“, a mogu je izazvati određeni lijekovi, npr. antidepresivi.
Nuedexta is suitable only for the treatment of PBA, not for other causes of emotional lability.
NUEDEXTA je prikladna samo za liječenje pseudobulbarnog afekta, ali ne i drugih uzroka emocionalne nestabilnosti.
Hypokalemia and hypomagnesemia should be corrected prior to initiation of therapy, and serum potassium and serum magnesium levels should be monitored during treatment if clinically indicated.
Hipokalijemiju i hipomagnezijemiju treba ispraviti prije započinjanja terapije, a koncentracije kalija i magnezija u serumu treba nadzirati za vrijeme liječenja, ako je klinički indicirano.
The European Medicines Agency has waived the obligation to submit the results of studies with NUEDEXTA in all subsets of the paediatric population in PBA (see section 4.2 for information on paediatric use).
Europska agencija za lijekove je izuzela obvezu podnošenja rezultata ispitivanja lijeka NUEDEXTA u svim podskupinama pedijatrijske populacije u pseudobulbarnom afektu (vidjeti dio 4.2 za informacije o pedijatrijskoj primjeni).
• Educational material for Healthcare Professionals (HCPs)
• edukacijski materijal za zdravstvene djelatnike
The pharmacokinetics of dextromethorphan/quinidine have not been investigated systematically in elderly subjects (aged >65 years) although such subjects were included in the clinical programme (14% ≥65 years, 2% ≥75 years).
Farmakokinetike dekstrometorfana / kinidina nisu sustavno ispitivane u starijih ispitanika (u dobi >65 godina) iako su takvi ispitanici bili uključeni u klinički program (14% ≥65 godina, 2% ≥75 godina).
There was no significant difference in the plasma concentrations of dextromethorphan and dextrorphan before and after the administration of memantine, and there was no effect on the plasma concentrations of memantine before and after the administration of dextromethorphan/quinidine.
Nije bilo značajne razlike u koncentracijama dekstrometorfana i dekstrorfana u plazmi prije i poslije primjene memantina i nije bilo učinka na koncentraciju memantina u plazmi prije i poslije primjene dekstrometorfana / kinidina.
As this medicinal product may cause foetal harm, it is not recommended during pregnancy and in women of childbearing potential not using contraception.
Budući da ovaj lijek može prouzročiti oštećenje fetusa, ne preporučuje se tijekom trudnoće niti u žena reproduktivne dobi koje ne koriste kontracepciju.
Quinidine inhibited CYP2D6 with a half maximal inhibitory concentration (IC50) of less than 0.05 µM.
Kinidin je inhibirao CYP2D6 uz pola maksimalne inhibitorne koncentracije (IC50) od manje od 0,05 µM.
Most cases remit when quinidine is withdrawn.
U većini se slučajeva povuče kada se prekine terapija kinidinom.
What NUEDEXTA looks like and contents of the pack
Kako NUEDEXTA izgleda i sadržaj pakiranja
• heart attack (myocardial infarction), heart palpitations
• srčani napadaj (infarkt miokarda), srčane palpitacije
Medicinal products that are dependent on CYP2D6 metabolism, especially those with a relatively narrow therapeutic index, should generally be avoided during treatment with NUEDEXTA, and patients must be instructed accordingly.
Lijekove koji ovise o metabolizmu CYP2D6, osobito one s relaitvno uskim terapijskim indeksom, treba općenito izbjegavati za vrijeme terapije NUEDEXTOM, a bolesnicima treba dati upute u skladu s tim.
• Serotonin syndrome
• serotoninski sindrom
Methods as to acidify the urine and dialysis are of no demonstrated benefit.
Metode zakiseljavanja mokraće i dijaliza nisu pokazale korist.
Quinidine is an inhibitor of P-glycoprotein.
Kinidin je inhibitor P-glikoproteina.
Administration of activated charcoal in conventional dose of 1 g/kg, administered every 2 to 6 hours as a slurry with 8 mL/kg of tap water may enhance the systemic elimination of quinidine; this measures should be avoided if an ileus is present.
Primjena aktivnog ugljena u konvencionalnoj dozi od 1 g/kg svakih 2 do 6 sati u polutekućem obliku, uz 8 ml/kg vode iz slavine, može povećati sistemsku eliminaciju kinidina; ovu mjeru treba izbjegavati ako postoji ileus.
Do not take NUEDEXTA if you have taken these antidepressants during the last two weeks and allow at least 14 days after stopping NUEDEXTA before starting an MAOI.
Ne uzimajte lijek NUEDEXTA ako ste uzimali te antidepresive u protekla dva tjedna i pustite da prođe najmanje 14 dana otkako ste prekinuli terapiju lijekom NUEDEXTA prije nego što počnete uzimati inhibitore monoaminoksidaze.
Hypersensitivity to the active substances or to any of the excipients listed in section 6.1.
Preosjetljivost na djelatnu tvar ili neku od pomoćnih tvari navedenih u dijelu 6.1.
Dextromethorphan hydrobromide is the pharmacologically active ingredient that acts on the central nervous system (CNS).
Dekstrometorfan hidrobromid je farmakološki aktivni sastojak koji djeluje na središnji živčani sustav (SŽS).
The recommended dose titration schedule is outlined below:
Titracija preporučene doze provodi se prema sljedećem rasporedu:
There are no or limited amount of data from the use of NUEDEXTA in pregnant women.
Nema podataka ili su podaci o primjeni lijeka NUEDEXTA u trudnica ograničeni.
• if you have a history of a liver disease (hepatitis) caused by quinidine
• ako ste u prošlosti imali bolest jetre (hepatitis) uzrokovanu kinidinom.
A review of the patient's current medicines is an essential part of the evaluation of patients for whom treatment with NUEDEXTA is proposed.
Provjera lijekova koje bolesnik trenutačno uzima važan je dio procjene bolesnika kojima se predlaže terapija NUEDEXTOM.
Dextromethorphan may increase the risk of serotonin syndrome (see Warnings and precautions and Possible side effects).
Dekstrometorfan može povećati rizik od serotoninskog sindroma (vidjeti Upozorenja i mjere opreza te Moguće nuspojave).
As NUEDEXTA may cause harm to your unborn baby, its use is not recommended when you are pregnant or if you are a women of childbearing potential not using contraception.
Budući da NUEDEXTA može naškoditi Vašem nerođenom djetetu, upotreba tog lijeka ne preporučuje kada ste trudni ili ako ste žena reproduktivnog potencijala koja ne rabi kontracepciju.
The exact mechanism by which dextromethorphan exerts therapeutic effects in patients with pseudobulbar affect is unknown.
Točni mehanizam kojim dekstrometorfan ostvaruje terapijski učinak u bolesnika s pseudobulbarnim afektom nije poznat.
• very rare (<1/10,000)
• vrlo rijetko (<1/10 000)
Serious adverse reactions have been reported for NUEDEXTA; these are muscle spasticity, respiratory depression and decreased oxygen saturation in the blood.
Za lijek NUEDEXTA prijavljene su ozbiljne nuspojave; to su mišićna spastičnost, depresija disanja i smanjena zasićenost krvi kisikom.
Ten patients discontinued study treatment due to ADRs, one of these patients due to a serious ADR (worsening muscle spasticity).
Deset bolesnika prekinulo je liječenje u sklopu ispitivanja zbog nuspojava na lijek, jedan od tih bolesnika zbog ozbiljne nuspojave na lijek (pogoršanje mišićne spastičnosti).
Use in older persons No special dose adjustment of NUEDEXTA is required in older patients.
U starijih bolesnika nije potrebna posebna prilagodba doze lijeka NUEDEXTA.
• Quinidine increases the amount of dextromethorphan in your body, by blocking the breakdown of dextromethorphan by the liver.
• Kinidin povećava količinu dekstrometorfana u Vašem tijelu time što blokira razgradnju dekstrometorfana u jetri.
Approximately 74% were Caucasian, 4% were Black, 1% were Asian and 19% were of Hispanic origin.
Otprilike njih 74% bili su bijelci, 4% crnci, 1% ispitanika bili su azijati a 19% latinoameričkog podrijetla.
Patients taking monoamine oxidase inhibitors (MAOIs) or who have taken MAOIs within the preceding 14 days due to the risk of serious and possibly fatal drug interactions, including serotonin syndrome.
Bolesnici koji uzimaju inhibitore monoaminoksidaze (MAOI) ili koji su uzimali MAOI unutar 14 proteklih dana zbog opasnosti od ozbiljne i možda smrtonosne interakcije lijekova, uključujući serotoninski sindrom.
• Dextromethorphan acts on the brain.
• Dekstrometorfan djeluje na mozak.
Blister of a PVC based clear film with aluminium foil seal.
Blister s prozirnim filmom na PVC podlozi, zatvoren aluminijskom folijom.
Drug abuse and dependence
Zloporaba lijeka i ovisnost
• excessively slow or shallow breathing (respiratory depression) and/or turning blue.
• prekomjerno sporo ili plitko disanje (depresija disanja) i/ili pojava plave boje kože.
• thioridazine, a medicine used in the treatment of schizophrenia and psychosis, that may affect the heart,
• tioridazin, lijek koji se koristi u liječenju shizofrenije i psihoze, a može utjecati na srce,
The patient alert card should be provided to all patients with instructions to carry it on them at all times.
Karticu s upozorenjima za bolesnika trebali bi dobiti svi bolesnici uz naputak da je uvijek nose sa sobom.
• you have a condition called myasthenia gravis (an autoimmune neuromuscular disease that causes muscle weakness and fatigability).
• ako imate bolest koja se naziva mijastenija gravis (autoimuna neuromišićna bolest koja uzrokuje mišićnu slabost i brzo umaranje).